Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives

Proprotein convertase subtilisin/kexin type 9 (PCSK9), also known as neural apoptosis regulated convertase (NARC1), is a key modulator of cholesterol metabolism. PCSK9 increases the serum concentration of low-density lipoprotein cholesterol by escorting low-density lipoprotein receptors (LDLRs) from...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Acta Pharmacol Sin
Main Authors: He, Ni-ya, Li, Qing, Wu, Chun-yan, Ren, Zhong, Gao, Ya, Pan, Li-hong, Wang, Mei-mei, Wen, Hong-yan, Jiang, Zhi-sheng, Tang, Zhi-han, Liu, Lu-shan
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2017
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342665/
https://ncbi.nlm.nih.gov/pubmed/28112180
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/aps.2016.134
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados